Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC [Seeking Alpha]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Seeking Alpha
Summary UCB announced plans to divest its entire current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. YolTech Therapeutics sold China rights for its PCSK9-targeting base editing therapeutic to Shenzhen Salubris Pharma in a $145 million agreement. Navigator Medicines raised $100 million in an initial funding to develop an OX40L-targeted portfolio that was in-licensed from Korea's IMBiologics. Lock Stock Deals and Financings Belgium's UCB ( OTCPK:UCBJF OTCPK:UCBJY ) announced plans to divest its entire current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets (see story ). It will sell this “mature” neurology and allergy portfolio for $680 million to CBC Group, a Singapore healthcare investor, and its partner, Mubadala, an Abu Dhabi sovereign fund. Meanwhile, UCB has eight neurology and immunology candidates in clinical development, most of them
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Non-GAAP EPS of -$0.28, revenue of $18.46M misses by $0.04M [Seeking Alpha]Seeking Alpha
- ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdatePR Newswire
- What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 11/7/24 - Beat
ADCT
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 8-K
- 11/13/24 - Form SC
- ADCT's page on the SEC website